Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
24.21
-0.19 (-0.78%)
At close: Oct 26, 2026, 4:00 PM EDT
24.22
+0.01 (0.04%)
Pre-market: Oct 27, 2026, 5:29 AM EDT
Viking Therapeutics Employees
Viking Therapeutics had 65 employees as of June 30, 2026. The number of employees increased by 16 or 32.65% compared to the same quarter last year. That makes Viking Therapeutics the 33,824th largest employer in the world and 4,468th in the United States.
Employees
65
Change (1Y)
16
Growth (1Y)
32.65%
Revenue / Employee
n/a
Profits / Employee
-$8,227,631
Market Cap
2.82B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Telix Pharmaceuticals | 1,184 |
| Arcus Biosciences | 601 |
| Denali Therapeutics | 507 |
| Tarsus Pharmaceuticals | 370 |
| Nurix Therapeutics | 317 |
| Dyne Therapeutics | 289 |
| Viridian Therapeutics | 252 |
VKTX News
- 4 days ago - Viking Therapeutics put volume heavy and directionally bearish - TheFly
- 5 days ago - Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026 - PRNewsWire
- 6 days ago - Viking Therapeutics price target lowered to $106 from $114 at Canaccord - TheFly
- 9 days ago - Viking Therapeutics Slides: Corporate presentation - Filings
- 12 days ago - Viking Therapeutics initiated with a Buy at UBS - TheFly
- 12 days ago - Viking Therapeutics initiated with a Buy at UBS - TheFly
- 12 days ago - Viking Therapeutics begins Sunrise Phase 3 clinical program - TheFly
- 12 days ago - Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity - PRNewsWire